NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Abaloparatide for treating osteoporosis in postmenopausal women [ID882]

Final Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company • Theramex (abaloparatide) Patient/carer groups • Action on Pain • Arthritis Action • Arthritis & Musculoskeletal Alliance • BackCare • Black Health Agency for Equality • Daisy Network • Menopause Charity • Menopause Matters • Menopause UK • Pain Concern • Pain Relief Foundation • Pain UK • Queermenopause • Royal Osteoporosis Society • South Asian Health Foundation • Specialised Healthcare Alliance • Women's Health Concern • Versus Arthritis Healthcare professional groups • British Dietetic Association • British Geriatrics Society • British Institute of Radiology • British Menopause Society • British Orthopaedic Association • British Pain Society • British Society for Rheumatology • British Society of Rehabilitative Medicine • Physiotherapy Pain Association • Royal College of General Practitioners • Royal College of Nursing	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee Comparator companies • Accord Healthcare (alendronic acid, ibandronic acid, teriparatide) • Accord-UK (raloxifene, risedronate sodium) • Amgen (denosumab) • Aristo Pharma (risedronate sodium, strontium ranelate) • Aspire Pharma (ibandronic acid, raloxifene, risedronate sodium) • Atnahs Pharma (ibandronic acid) • Aurobindo Pharma - Milpharm (alendronic acid, risedronate sodium) • Dr. Reddy's Laboratories (zoledronic acid) • Eli Lilly (teriparatide)

Consultees	Commentators (no right to submit or appeal)
• Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • Society for Endocrinology • UK Clinical Pharmacy Association <u>Others</u> • Department of Health and Social Care • NHS England	• Gedeon Richter (teriparatide) • Internis Pharmaceuticals (alendronic acid) • Mylan (ibandronic acid) • Novartis (zoledronic acid) • Organon Pharma (alendronic acid) • Ranbaxy (UK) Limited a Sun Pharmaceutical Company (zoledronic acid) • Rosemont (alendronic acid) • Sandoz (risedronate sodium, ibandronic acid) • Seacross Pharmaceuticals (zoledronic acid) • Teva UK (teriparatide) • Thornton & Ross (teriparatide) • UCB Pharma (romosozumab) • Vygoris (raloxifene) • Zentiva (ibandronic acid) <u>Relevant research groups</u> • Bone Research Society • Chronic Pain Policy Coalition • Cochrane Gynaecology and Fertility Group • Cochrane Metabolic & Endocrine Disorders Group • Cochrane Musculoskeletal Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute of Health Research <u>Associated Public Health groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non company consultees are invited to submit statements relevant to the group they are representing.

